Abstract
The treatment of HIV-1/AIDS has achieved great success, partly owing to the clinical applications of HIV-1 integrase (IN) strand transfer inhibitors (INSTIs). After briefly introducing HIV-1/AIDS and its treatment, this chapter discusses the medical applications and limitations of five US Food and Drug Administration–approved INSTIs for the treatment of HIV/AIDS and preexposure prophylaxis for HIV-1. The development of authentic HIV-1 IN inhibitors, which include two main categories, INSTIs and IN-LEDGF/p75 allosteric inhibitors, is then reviewed. Pharmacophore and binding modes of INSTIs are provided, which are helpful for designing and identifying better novel INSTIs that may overcome the emergence of resistance to marketed INSTIs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
